- Home
- USIO vs LEXX Comparison
USIO vs LEXX Comparison
Compare USIO & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- LEXX
- Stock Information
- Founded
- USIO 1998
- LEXX 2004
- Country
- USIO United States
- LEXX Canada
- Employees
- USIO N/A
- LEXX N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- LEXX Health Care
- Exchange
- USIO Nasdaq
- LEXX Nasdaq
- Market Cap
- USIO 37.8M
- LEXX 39.1M
- IPO Year
- USIO N/A
- LEXX N/A
- Fundamental
- Price
- USIO $1.61
- LEXX $1.75
- Analyst Decision
- USIO Strong Buy
- LEXX Strong Buy
- Analyst Count
- USIO 2
- LEXX 2
- Target Price
- USIO $5.00
- LEXX $9.50
- AVG Volume (30 Days)
- USIO 795.8K
- LEXX 231.5K
- Earning Date
- USIO 03-26-2025
- LEXX 01-10-2025
- Dividend Yield
- USIO N/A
- LEXX N/A
- EPS Growth
- USIO N/A
- LEXX N/A
- EPS
- USIO 0.13
- LEXX N/A
- Revenue
- USIO $81,027,258.00
- LEXX $496,923.00
- Revenue This Year
- USIO $2.94
- LEXX $20.39
- Revenue Next Year
- USIO $14.59
- LEXX $113.25
- P/E Ratio
- USIO $12.37
- LEXX N/A
- Revenue Growth
- USIO N/A
- LEXX 77.63
- 52 Week Low
- USIO $1.24
- LEXX $1.62
- 52 Week High
- USIO $2.92
- LEXX $6.85
- Technical
- Relative Strength Index (RSI)
- USIO 42.91
- LEXX 37.67
- Support Level
- USIO $1.77
- LEXX $1.67
- Resistance Level
- USIO $1.96
- LEXX $1.90
- Average True Range (ATR)
- USIO 0.21
- LEXX 0.20
- MACD
- USIO -0.10
- LEXX -0.01
- Stochastic Oscillator
- USIO 3.33
- LEXX 23.81
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for the Output Solutions operations.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.